Document is current
Any future updates will be listed below
-
Authors
Yamamoto, Yuta
Watanabe, Tatsuro https://orcid.org/0000-0002-4166-4781
Ureshino, Hiroshi https://orcid.org/0000-0002-5034-3699
Kurahashi, Yuki
Fukuda-Kurahashi, Yuki
Kamachi, Kazuharu
Kawasoe, Kazunori
Kidoguchi, Keisuke
Yamashita, Satoshi
Hattori, Naoko
Ushijima, Toshikazu https://orcid.org/0000-0003-3405-7817
Kimura, Shinya https://orcid.org/0000-0003-1717-6208
-
Funding
Funding for this research was provided by:
OHARA Pharmaceutical Co.,Ltd.
- License Information
-
More Information
Article History
Received: 14 February 2024
Revised: 24 May 2024
Accepted: 30 May 2024
First Online: 5 June 2024
Competing interests
: YK and YFK are full-time employees of OHARA Pharmaceutical Co. SK has received honoraria from OHARA Pharmaceutical Co., Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals, and research funding from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals. The other authors declare no competing interests.
